Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

Inc. and its subsidiary Citius Oncology, Inc. have announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for their drug LYMPHIR by the Centers for Medicare & ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Qartemi, India’s first international CAR T-cell therapy, is approved for the treatment of adult non-hodgkin lymphoma (NHL). Licensed from Hospital Clínic de Barcelona (HCB), a globally renowned ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

Types of immunotherapy used to treat stage 4 lymphoma include: CAR T-Cell Therapy This is a type of immunotherapy where your doctor will remove some of your T cells, add special receptors to their ...

Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with HyBryte over up to 54 weeks. Also Read: Soligenix Kickstarts ...